Renin-angiotensin System Antagonists and Beta-blockers in Prevention of Anthracycline Cardiotoxicity: a Systematic Review and Meta-analysis.
Monica Samuel AvilaSuellen Rodrigues Rangel SiqueiraLucas WaldeckSilvia Moreira Ayub-FerreiraRichard TakxMarcio Sommer BittencourtEdimar Alcides BocchiPublished in: Arquivos brasileiros de cardiologia (2023)
The use of RAAS inhibitors and beta-blockers to prevent anthracycline-induced cardiotoxicity was associated with less pronounced reduction in LVEF, higher final LVEF, and lower incidence of heart failure. No changes in mortality were observed. (CRD PROSPERO 42019133615).